论文部分内容阅读
帕米膦酸二钠(博宁)是新一代的抗骨溶解剂,其学名是3—氨基—1—羟基丙叉—1,1—双膦酸盐。由深圳海王医药集团和南京药物研究所研制和生产。临床前的研究已经证实,该药对体外破骨细胞性骨吸收有明显的直接抑制作用,对动物溶骨性病变所致的血钙和尿钙升高也有明显的纠正作用。经Ⅱ期临床研究证实,该药对治疗恶性肿瘤骨转移引起的溶骨并由此出现的高血钙和骨痛等症状有明显的疗效。为进一步评价帕米膦酸二钠的疗效和不良反应,现将43家单位对该药进行的Ⅲ
Pamidronate disodium (Bonin) is a new generation of anti-osteolytic agent, its scientific name is 3-amino-1-hydroxy-propylidene-1,1-bisphosphonate. Developed and manufactured by Shenzhen Neptunus Pharmaceutical Group and Nanjing Institute of Materia Medica. Preclinical studies have confirmed that the drug has a clear direct inhibitory effect on osteoclastic bone resorption in vitro and also has a significant correction on the increase of serum calcium and urinary calcium caused by osteolytic lesions in animals. The clinical research confirmed that the drug, the drug for the treatment of malignant bone metastases caused by osteolytic osteolytic and the resulting symptoms such as hypercalcemia and bone pain have obvious curative effect. In order to further evaluate the efficacy and adverse reactions of pamidronate disodium, now 43 units of the drug for Ⅲ